Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals (Nasdaq: SNDX) announced inducement equity awards on November 1, 2025, granting options to purchase up to 143,500 shares of common stock to four new employees under its 2023 Inducement Plan.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Syndax Pharmaceuticals (Nasdaq: SNDX) announced inducement equity awards on November 1, 2025, granting options to purchase up to 143,500 shares of common stock to four new employees under its 2023 Inducement Plan.
The options vest over four years: 25% at the one-year anniversary of the vesting commencement date and 1/48th monthly thereafter for the remaining 36 months, subject to continued service through each vesting date.
Details
News Market Reaction – SNDX
On Nov 6, the first trading day after this news, SNDX closed 2.72% below the previous close.
Data tracked by StockTitan Argus for the Nov 6 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on November 1, 2025, the Company granted inducement awards to purchase up to 143,500 shares of common stock to four new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.